Cyclosporine metabolic side effects: Association with the WNK4 system

European Journal of Clinical Investigation

Volumn 41, Issue 10, 2011, Pages 1113-1120

  Melnikov, Semyon ^a   Mayan, Haim ^b   Uchida, Shinichi ^c   Holtzman, Eliezer J ^b   Farfel, Zvi ^b  

^a Laboratory of Biochemical Pharmacology   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Cyclosporine; Familial hyperkalemia and hypertension (FHHt); Hypercalciuria; Na Cl cotransporter (NCC); WNK4 kinase

Indexed keywords

CALCIUM; CYCLOSPORIN; MESSENGER RNA; POTASSIUM; PROTEIN KINASE WNK4; SODIUM; SODIUM CHLORIDE COTRANSPORTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CHEMISTRY; BLOOD PRESSURE; CALCIUM URINE LEVEL; CONTROLLED STUDY; DRUG EXPOSURE; FAMILIAL HYPERKALEMIA HYPERTENSION SYNDROME; HYPERCALCIURIA; HYPERKALEMIA; HYPERTENSION; MALE; NONHUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SODIUM RETENTION; SODIUM URINE LEVEL; TREATMENT DURATION;

ANALYSIS OF VARIANCE; ANIMALS; CYCLOSPORINE; HUMANS; HYPERCALCIURIA; HYPERKALEMIA; HYPERTENSION; IMMUNOBLOTTING; IMMUNOSUPPRESSIVE AGENTS; MALE; PROTEIN-SERINE-THREONINE KINASES; PSEUDOHYPOALDOSTERONISM; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SODIUM CHLORIDE SYMPORTERS;

EID: 80052633099     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02517.x     Document Type: Article

References (34)

1. Bantle JP, Boudreau RJ, Ferris TF. Suppression of plasma renin activity by cyclosporine. Am J Med 1987;83:59-64.
2. Curtis JJ, Luke RG, Jones P, Diethelm AG. Hypertension in cyclosporine - treated renal transplant recipients is sodium dependent. Am J Med 1988;85:134-8.
3. Wang J, Zhang Z-R, Chou C-F, Liang Y-Y, Gu Y, Ma H-P. Cyclosporine stimulates the renal epithelial sodium channel by elevating cholesterol. Am J Physiol Renal Physiol 2009;296:F284-90.
4. Wu MS, Yang CW, Bens M, Peng KC, Yu HM, Vanderwalle A. Cyclosporine stimulates Na-K-Cl cotransport activity in cultured mouse medullary thick ascending limb cells. Kidney Int 2000;58:1652-63.
5. Lim SW, Ahn KO, Sheen MR, Jeon US, Kim J, Yang CW et al. Down regulation of renal sodium transporters and tonicity responsive enhancer binding protein by long-term treatment with cyclosporine A. J Am Soc Nephrol 2007;18:421-9.
6. Deppe CE, Heering PJ, Tinel H, Kinne-Safran E, Grabensee B, Kinne RHH. Effect of cyclosporine A on Na-K-ATPase, Na-K-2Cl cotransporter, and H-K-ATPase in MDCK cells and two subtypes, C7 and C11. Exp Nephrol 1997;5:471-80.
7. Esteva-Font C, Ars E, Guillen-Gomez E, Campistol BM, Sanz J, Jimenez W et al. Cyclosporine-induced hypertension is associated with increased sodium transporter of the loop of Henle (NKCC2). Nephrol Dial Transplant 2007;22:2810-6.
8. Aker S, Heering P, Kinne-Safran E, Deppe C, Grabensee B, Kinne RKH. Different effects of cyclosporine A and FK506 on potassium transport systems in MDCK cells. Exp Nephrol 2001;9:332-40.
9. Kamel KS, Ethier JH, Quaggin S, Levin A, Albert S, Carlisle EJF et al. Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine. J Am Soc Nephrol 1991;2:1279-84.
10. 28k expression by cyclosporine A in rat kidney: the possible pathogenesis of cyclosporine A-induced hypercalciuria. J Am Soc Nephrol 1998;9:1416-26.
11. 28k knockout and wild-type mice. Kidney Int 2002;62:2055-61.
12. Mayan H, Vered I, Mouallem M, Tzadok-Witkon M, Pauzner R, Farfel Z. Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J Clin Endocrinol Metab 2002;87:3248-54.
13. Wilson F, Disse-Nicodeme S, Choate K, Ishikawa K, Nelson-Wiliams C, Desitter I et al. Human hypertension caused by mutations in WNK kinases. Science 2001;293:1107-12.
14. Mayan H, Munter G, Shaharabany M, Mouallem M, Pauzner R, Holtzman EJ et al. Hypercalciuria in familial hyperkalemia and hypertension accompanies hyperkalemia and precedes hypertension; description of a large family with the Q565E. WNK4 mutation. J Clin Endocrinol Metab 2004;89:4025-30.
15. Lalioti MD, Zhang J, Volkman HM, Kahle KT, Hoffman KE, Toka HR et al. Wnk4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. Nat Genet 2006;38:1124-32.
16. Mayan H, Melnikov S, Novikov I, Holtzman JE, Farfel Z. Familial hyperkalemia and hypertension: pathogenetic insights based on lithium clearance. J Clin Endocrinol Metab 2009;94:3010-6.
17. Wilson FH, Kahle KT, Sabath E, Lalioty MD, Rapson AK, Hoover RS et al. Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci U S A 2003;100:680-4.
18. Yang CL, Angell J, Mitchell R, Ellison DH. WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J Clin Invest 2003;111:1039-45.
19. + secretion. Nat Genet 2003;35:372-6.
20. Yamauchi K, Rai T, Kobayashi K, Sohara E, Suzuki T, Itoh T et al. Disease-causing mutant WNK4 increases paracellular chloride permeability and phosphorylates claudins. Proc Natl Acad Sci USA 2004;101:4690-4.
21. Kahle KT, Macgregor GG, Wilson FH, Van Hoek AN, Brown D, Ardito T et al. Paracellular Cl- permeability is regulated by WNK4 kinase: insight into normal physiology and hypertension. Proc Natl Acad Sci USA 2004;101:14877-82.
22. Schambelan M, Sebastian A, Rector FG Jr. Mineralocorticoid-resistant renal hyperkalemia without salt waisting (type II pseudohypoaldosteronism): role of increased renal chloride reabsorption. Kidney Int 1981;19:716-27.
23. Ko B, Joshi LM, Cooke LL, Vasquez N, Musch MW, Hebert SC et al. Phorbol ester stimulation of RasGRP1 regulates the sodium-chloride cotransporter by a PKC-independent pathway. Proc Natl Acad Sci USA 2007;104:20120-5.
24. San-Cristobal P, Pacheco-Alvarez D, Richardson C, Ring AM, Vazquez N, Rafiqi FH et al. Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway. Proc Natl Acad Sci U S A 2009;106:4384-9.
25. Talati G, Ohta A, Rai T, Sohara E, Naito S, Vandewalle A et al. Effect of angiotensin II on the WNK-OSR1/SPAK-NCC phosphorylation cascade in cultured mpkDCT cells and in vivo mouse kidney. Biochem Biophys Res Commun 2010;393:844-8.
26. You CW, Park YH, Lee ES, Kim YJ, Shin SM, Park MO. Effects of thyroxin on hyperkalemia and renal cortical Na-K-ATPase activity induced by cyclosporine A. J Korean Med Sci 2002;17:625-32.
27. Aicher L, Meier G, Norcross AJ, Jakubowsky J, Varela MC, Cordier A et al. Decrease in kidney calbindin-D 28kDa as a possible mechanism mediating cyclosporine A- and FK-506-induced calciuria and tubular mineralization. Biochem Pharmacol 1997;53:723-31.
28. Shaharabany M, Holtzman EJ, Mayan H, Hirschberg K, Seger R, Farfel Z. Distinct pathways for the involvement of WNK4 in the signaling of hypertonicity and EGF. FEBS J 2008;275:1631-42.
29. Lee HC, Kim S, Kang SM, Kim GH. The effects of cyclosporine on tight junction proteins and transepithelial electrical resistance in MDCK cells. Abstract, ASN conference, San Diego, CA, 2009.
30. (D561A/+) knockin mouse model. Cell Metab 2007;5:331-4.
31. Mayan H, Attar-Herzberg D, Shaharabany M, Holtzman EJ, Farfel Z. Increased urinary Na-Cl cotransporter protein in familial hyperkalemia and hypertension. Nephrol Dial Transplant 2008;23:492-6.
32. - cotransporter by the WNK-regulated kinases SPAK and OSR1. J Cell Sci 2008;121:675-84.
33. Ohta A, Rai T, Yui N, Chiga M, Yang SS, Lin HS et al. Targeted disruption of the Wnk4 gene decreases phosphorylation of Na-Cl cotransporter, increases Na excretion and lowers blood pressure. Hum Mol Genet 2009;18:3978-86.
34. Cha SK, Huang CL. WNK4 kinase stimulates caveolae-mediated endocytosis of TRPV5 amplifying the dynamic range of regulation of the channel by protein kinase C. J Biol Chem 2010;285:6604-11.